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 33 
Osteoarthritis is the most common musculoskeletal disease and the leading cause of disability 34 
globally. Here, we perform a genome-wide association study for osteoarthritis (77,052 cases and 35 
378,169 controls), analysing 4 phenotypes: knee osteoarthritis, hip osteoarthritis, knee and/or hip 36 
osteoarthritis, and any osteoarthritis. We discover 64 signals, 52 of them novel, more than 37 
doubling the number of established disease loci. Six signals fine map to a single variant. We 38 
identify putative effector genes by integrating eQTL colocalization, fine-mapping, human rare 39 
disease, animal model, and osteoarthritis tissue expression data. We find enrichment for genes 40 
underlying monogenic forms of bone development diseases, and for the collagen formation and 41 
extracellular matrix organisation biological pathways. Ten of the likely effector genes, including 42 
TGFB1, FGF18, CTSK and IL11 have therapeutics approved or in clinical trials, with mechanisms of 43 
action supportive of evaluation for efficacy in osteoarthritis. 44 
 45 
 46 
Osteoarthritis affects 40% of individuals over the age of 701, is a major cause of pain, comorbidity 47 
and mortality2. Ten million people in the UK alone suffer from osteoarthritis, with a total indirect 48 
cost to the economy of £14.8 billion per annum2. Disease management targets the main symptom 49 
(pain) and culminates in joint replacement surgery (1.76 million per year in the EU) with variable 50 
outcomes3. There is a clear and urgent need to translate genomic evidence into druggable 51 
mechanisms of disease aetiology and progression, to support the development of disease-modifying 52 
therapies for osteoarthritis. 53 
 54 
Here, we leverage the UK Biobank and arcOGEN resources to perform a genome-wide meta-analysis 55 
for osteoarthritis across ~17.5 million single nucleotide variants in up to 455,221 individuals 56 
(Supplementary Figure 1). We identify 65 genome-wide significant variants at 64 loci (Pч3x10-8; 57 
Online Methods, Supplementary Table 1), 52 of which are novel, thus increasing the number of 58 
established loci from 344 to 86: 24 novel signals for osteoarthritis at any site (77,052 cases), 15 for 59 
hip osteoarthritis (15,704 cases), 7 for knee osteoarthritis (24,955 cases), and 6 for osteoarthritis of 60 
the hip and/or knee (39,427 cases) (Table 1, Supplementary Figures 2-6, Supplementary Tables 2 and 61 
3). We find that 25 of 34 previously-reported loci show association (P<0.05) with at least one of the 62 
four osteoarthritis traits we evaluate (Supplementary Table 4).  63 
 64 
To identify putative effector genes at the 64 genome-wide significant regions, we integrated results 65 
from several strands of investigation, including transcriptomic/proteomic characterisation of primary 66 
tissue from osteoarthritis patients undergoing joint replacement surgery, coupled with statistical 67 
fine-mapping, annotation of predicted consequences of variants in the credible sets, eQTL 68 
colocalization, and relevant rare human disease and animal model evidence (Online Methods, 69 
Supplementary Table 5 and 6). We observe evidence of colocalization in at least one tissue for 49 70 
out of the 64 loci, 44 of which are at newly-associated osteoarthritis signals (Supplementary Table 7 71 
and Supplementary Figure 7). Using MetaXcan, we identify 11 genes with additional evidence of 72 
colocalization at loci not reaching genome-wide significance in SNV analyses (Supplementary Figure 73 
8, Supplementary Tables 8 and 9). 74 
 75 
Pathway analyses (Online Methods and Supplementary Note) identify 64 biological processes 76 
associated with osteoarthritis, of which 46 are bone-, cartilage- and chondrocyte- morphology 77 
related (Supplementary Table 10). The collagen formation and extracellular matrix organisation 78 
biological pathways are consistently identified by different pathway analysis methods. Genome-wide 79 
linkage disequilibrium (LD) score regression analysis5,6 unveils significant correlation between 80 
osteoarthritis and traits within the obesity, cognition, smoking, bone mineral density and 81 
reproductive trait categories (Figure 1; Supplementary Table 11 and 12). Mendelian randomization 82 
analyses (Online Methods) support a role for higher body mass index (BMI) and adiposity in 83 
osteoarthritis risk, and identify a potential protective effect of LDL cholesterol, and of higher level of 84 
education against osteoarthritis (Supplementary Tables 13-15 and Supplementary Note). Two of the 85 
BMI loci (SLC39A8 and FTO) show genome-wide significant associations with osteoarthritis, with 86 
SLC39A8 showing much larger effects on osteoarthritis than expected given the BMI-raising effects 87 
(Supplementary Figure 9). Apparent causal associations of knee pain with osteoarthritis 88 
(Supplementary Table 13 and 16) are potentially attributable to reverse causality (Supplementary 89 
Note). We estimate the proportion of the total narrow sense heritability explained by osteoarthritis 90 
loci to be 14.7 % for knee osteoarthritis, 51.9 % for hip osteoarthritis, 24.2% for osteoarthritis of the 91 
hip and/or knee, and 22.5% of osteoarthritis at any site (Supplementary Table 17). We do not find 92 
evidence for a role of low-frequency or rare variation of large effect in osteoarthritis susceptibility, 93 
and have limited power to detect smaller effects at lower-frequency variants (Figure 2). In the 94 
future, meta-analyses of osteoarthritis studies in global populations will help further deconvolute 95 
the genetic underpinning of this disabling disease. 96 
 97 
We used a combination of conditional analyses7 followed by asymptotic Bayes factor fine-mapping8 98 
(Online Methods) of conditionally distinct association signals to identify causal variants. In six of the 99 
novel loci, a single variant could be postulated as causal with more than 95% posterior probability: 100 
missense variants in SLC39A8, IL11 and ANAPC4 (rs13107325, rs4252548 and rs34811474, 101 
respectively), rs75621460 near TGFB1, rs547116051 near MAPT and rs528981060 near SCUBE1 102 
(Supplementary Table 18 and Supplementary Note).  103 
 104 
We observe strong enrichment for genes known to cause monogenic bone development diseases 105 
and forms of early-onset osteoarthritis, in the vicinity of osteoarthritis signals (odds ratio [OR] 8.87, 106 
P=1.8x10
-4
, and OR 8.83, P=8x10
-3
, respectively) (Supplementary Table 19 and 20). This finding 107 
highlights bone development as an important physiological process in osteoarthritis aetiology. 108 
Several genes identified as likely causal in our study are also linked to osteoarthritis aetiology in 109 
animal models. In eight out of the ten cases where we can unequivocally define directionality of 110 
association, we observe concordance between our results and those from animal models (i.e. that 111 
reduced expression or loss-of-function mutations increase osteoarthritis risk both in humans and in 112 
animal models) (Supplementary Table 21). Some of these genes code for structural bone/cartilage 113 
proteins (COL11A1, COL11A2) or play a critical role in bone/cartilage development (FGFR3, GDF5). 114 
These consistent observations in human and animal models provide compelling evidence for a causal 115 
role of these genes in osteoarthritis and point to an agonist strategy as the desired mechanism of 116 
action for new osteoarthritis drugs targeting these eight genes.  117 
 118 
Ten genes have a therapeutic approved or in clinical trials (Table 2), with mechanisms of action that 119 
are not inconsistent with potential for efficacy in osteoarthritis, based on eQTL, functional genomics, 120 
rare disease and animal model data. Four of these genes, TGFB1, GDF5, FGF18 and CTSK, currently 121 
have therapeutics in clinical development for osteoarthritis/cartilage regeneration indications. Of 122 
these, only GDF5 has been previously published as genetically associated with osteoarthritis 123 
susceptibility9. Two of the genes, IL11 and DPEP1, have approved therapeutics for unrelated 124 
indications, opening the possibility for repositioning.  125 
 126 
rs4252548 (hip osteoarthritis, posterior probability of causality [PPC] 0.99), is a predicted deleterious 127 
missense variant (Arg112His) in IL11 (interleukin 11), associated with increased risk of hip 128 
osteoarthritis. Using RNA sequencing (Online Methods), we find that IL11 shows increased 129 
expression in degraded compared to intact cartilage (log2 fold change [logFC]=0.787, false discovery 130 
rate [FDR]=4.82x10-3). This cytokine is a potent stimulator of bone formation10, is required for 131 
normal bone turnover11 and has been previously found to be up-regulated in osteoarthritis knee 132 
tissue and to be associated with disease progression12. The rs4252548 osteoarthritis risk allele is also 133 
associated with decreased adult height13. A recombinant human IL11 molecule (NEUMEGA) with 134 
three-fold-enhanced affinity for IL11RA, compared to IL1114, is approved for the treatment of 135 
chemotherapy-induced thrombocytopenia (Table 2). The likely effects of increased IL11 signalling in 136 
osteoarthritis joints are currently not well understood, and it is worth evaluating this therapeutic for 137 
potential efficacy in disease models. 138 
 139 
The rs1126464 (osteoarthritis, PPC 0.89) locus index signal is a missense variant (Glu351Gln) in 140 
DPEP1, predicted to be tolerated. DPEP1 hydrolyses a wide range of dipeptides, and is implicated in 141 
the renal metabolism of glutathione and its conjugates. A DPEP1 inhibitor, cilastatin, is approved and 142 
used in combination with the antibiotic imipenem, in order to protect it from dehydropeptidase and 143 
prolong its antibacterial effect15. We suggest investigating the effects of cilastatin in osteoarthritis 144 
models to determine whether this has potential as a therapeutic, or whether an agonist may be 145 
efficacious. 146 
 147 
rs75621460 (hip and/or knee osteoarthritis, single variant in the 95% credible set) is an intergenic 148 
variant residing downstream of CCDC97 and TGFB1 (Table 1, Supplementary Table 3), and is 149 
colocalised with a TGFB1 eQTL in sun-exposed skin (GTEx) (Supplementary Table 6). Mutations in 150 
TGFB1 cause CamuratiEngelmann disease characterised by diaphyseal dysplasia with thickening 151 
and fluctuating bone volume giving rise to bone pain, muscle weakness, gait issues and tiredness16,17. 152 
TGFB1 plays a critical role in skeletal development and adult bone homeostasis18, including bone 153 
remodelling19, osteoclast/osteoblast differentiation20,21 and chondrogenesis22. INVOSSATM, a TGFB1 154 
cell and gene therapy in chondrocytes, was associated with significant improvements in function and 155 
pain in patients with knee osteoarthritis23. 156 
 157 
The importance of TGFB1 signalling for osteoarthritis is supported by significant enrichment for TGF 158 
Beta Signalling Pathway genes (Supplementary table 10), including: LTBP1, LTBP3, SMAD3 and 159 
RUNX2. LTBP1, at the novel rs4671010 locus, encodes Latent-transforming growth factor beta-160 
binding protein 1 which directly interacts with TGFB1, is involved in the assembly, secretion and 161 
targeting of TGFB1 to sites at which it is stored and/or activated, and may contribute to controlling 162 
the activity of TGFB124. LTBP3 (novel locus: rs10896015) encodes Latent-transforming growth factor 163 
beta-binding protein 3 which directly interacts with and activates TGFB1 in the early proliferative 164 
phase of osteogenic differentiation25. SMAD3 (known locus: rs12901372) encodes a transcriptional 165 
modulator and plays a critical role in chondrogenic differentiation, and regulates TGFB1 166 
expression26; and the TGFB1/SMAD3 pathway regulates the expression of miR-140 in 167 
osteoarthritis27. The directionality of the colocalized eQTL and animal model data suggest that 168 
agonism/up-regulation of LTBP1, LTBP3 and SMAD3 may be therapeutic for osteoarthritis 169 
(Supplementary Table 21). RUNX2 (known locus: rs2064630) encodes a transcription factor essential 170 
for the osteoblast differentiation and chondrocyte maturation28, and is down-regulated by TGFB129. 171 
Given the genetic and biological support for the importance of TGFB1 in osteoarthritis aetiology and 172 
treatment, there may be scope for the development of simpler osteoarthritis therapeutics which 173 
target this mechanism, such as a small molecule or antibody. 174 
 175 
Although not a current drug target, the novel SLC39A8 association is noteworthy. rs13107325 176 
(osteoarthritis, PPC 0.99) is a missense variant located in SLC39A8 and demonstrates significantly 177 
increased expression in degraded compared to intact articular cartilage (logFC=0.522, FDR=5.80x10-178 
5) (Table1; Supplementary Table 2), consistent with previously-reported increased levels of SLC39A8  179 
in osteoarthritis compared to healthy chondrocytes30,31. rs13107325 is also associated with obesity32, 180 
hypertension33, Crohn's disease and altered microbiome composition34. SLC39A8 encodes a zinc 181 
transporter ZIP8 which functions in the cellular import of zinc at the onset of inflammation. 182 
Suppression of SLC39A8 has been shown to reduce cartilage degradation in osteoarthritis animal 183 
models30. The zinc-SLC39A8-MTF1 axis has been proposed to be an essential catabolic regulator of 184 
osteoarthritis pathogenesis31.  185 
 186 
In this study, we have more than doubled the number of osteoarthritis risk loci, supported by 187 
integrated eQTL colocalization, fine-mapping, Mendelian bone disease, animal model and 188 
differential osteoarthritis joint expression data, to reveal putative effector genes. In addition to 189 
identifying chondrocyte and osteoblast biological mechanisms implicated in osteoarthritis 190 
susceptibility, we have revealed biological mechanisms that represent attractive targets for 191 
osteoarthritis drug discovery, and highlight approved therapeutics which represent viable 192 
considerations for repositioning as osteoarthritis therapies. We anticipate that this advance in basic 193 
understanding of osteoarthritis risk factors and mechanisms will stimulate the evaluation of novel 194 
drug targets for osteoarthritis. 195 
 196 
 197 
 198 
 199 
 200 
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FIGURE LEGENDS 320 
Figure 1: Genetic correlations between osteoarthritis and other traits and diseases. Genetic 321 
correlations (rg) between osteoarthritis and other publicly available GWAS results, based on LD 322 
score regression as implemented in LDHub. The diagram shows traits with significant correlation 323 
(P<0.05) and 95% confidence intervals across all osteoarthritis definitions. The red outline of the 324 
bars denotes negative correlation and the blue outline denotes positive correlation. The upper right 325 
legend shows the categories of the traits. OA: osteoarthritis; OA_hip: Hip osteoarthritis; OA_knee: 326 
Knee osteoarthritis; OA_kneehip: Knee and/or hip osteoarthritis. Lumbar spine bone mineral density 327 
1 and 2 relate to two different published studies. 328 
 329 
Figure 2: Allelic architecture of index variants. Meta-analysis based odds ratio with its 95% 330 
confidence interval of 99 variants (previously-reported denoted as circles and newly-reported 331 
denoted as diamonds) with UK Biobank and arcOGEN meta-analysis P<3.0x10-8 (two-sided) as a 332 
function of their weighted allele frequency. The curves indicate 80% power at the genome-wide 333 
significance threshold of Pч3.0x10-8, for the four sample sizes of the meta-analyses. We have 80% 334 
power to detect an association at genome-wide significance for a variant with 1% MAF and allelic 335 
odds ratio of 1.19, 1.40, 1.32 and 1.25 for all osteoarthritis, hip osteoarthritis, knee osteoarthritis 336 
and knee and/or hip osteoarthritis, respectively. For 0.1% MAF the corresponding odds ratios are 337 
1.66, 2.43, 2.12 and 1.90. 338 
  339 
Table 1: Independent variants with P<3x10
-8
 in an inverse-variance weighted fixed effects meta-340 
analysis of UK Biobank and arcOGEN. Variant positions are reported according to build 37 and their 341 
alleles are coded based on the positive strand.  342 
 343 
rsID Trait Other Traits EA/NEA WEAF OR OR_95CI PV q_pv i2 
           
Newly Identified Loci 
rs4338381 OA_hip 
OA             
OA_kneehi
p 
A/G 0.63 1.1 1.07, 1.13 4.37E-15 0.93 0 
1:150214028 OA OA_hip C/CT 0.37 1.03 1.02, 1.05 2.54E-08 1.00 0 
1:174192402 OA 
 
TAAAAAA
AAAAAA
AAAAA/T 
0.57 1.03 1.02, 1.05 1.05E-08 1.00 0 
rs11583641 OA_hip 
 
C/T 0.72 1.08 1.06, 1.11 5.58E-10 0.63 0 
rs10218792 OA 
 
G/T 0.27 1.04 1.02, 1.05 2.03E-08 0.77 0 
rs2061027 OA 
OA_knee  
OA_kneehi
p 
A/G 0.51 1.04 1.03, 1.05 3.16E-13 0.25 25.8 
rs12470967 OA_knee 
OA_kneehi
p 
A/G 0.43 1.06 1.04, 1.08 1.50E-08 1.00 0 
rs62182810 OA 
 
A/G 0.55 1.03 1.02, 1.05 1.65E-09 0.84 0 
rs62262139 OA 
 
A/G 0.54 1.04 1.03, 1.05 9.09E-11 1.00 0 
rs11732213 OA_kneehip 
OA             
OA_hip 
T/C 0.81 1.06 1.04, 1.08 8.81E-10 0.60 0 
rs1913707 OA_hip OA A/G 0.61 1.08 1.06, 1.11 2.96E-11 0.03 79 
rs34811474 OA 
 
G/A 0.77 1.04 1.03, 1.05 2.17E-09 0.76 0 
rs13107325 OA 
 
T/C 0.08 1.1 1.07, 1.12 8.29E-19 0.70 0 
rs35611929 OA_knee 
 
A/G 0.34 1.06 1.04, 1.08 1.21E-08 0.96 0 
rs3884606 OA_kneehip 
 
G/A 0.49 1.04 1.03, 1.06 8.25E-09 0.42 0 
rs115740542 OA 
OA_hip  
OA_kneehi
p 
C/T 0.07 1.06 1.04, 1.08 8.59E-09 0.95 0 
rs9277552 OA_kneehip 
OA_knee         
OA 
C/T 0.79 1.06 1.04, 1.08 2.37E-10 0.78 0 
rs12154055 OA 
 
G/A 0.61 1.03 1.02, 1.04 2.71E-08 0.10 63.5 
rs80287694 OA_hip 
 
G/A 0.11 1.12 1.08, 1.16 2.66E-09 0.20 39.1 
rs11409738 OA 
OA_kneehi
p 
TA/T 0.37 1.04 1.03, 1.05 2.13E-10 1.00 0 
rs330050 OA 
OA_kneehi
p OA_hip 
G/C 0.51 1.04 1.03, 1.05 1.93E-11 0.35 0 
rs60890741 OA_hip 
 
C/CA 0.86 1.11 1.08, 1.16 4.50E-09 1.00 0 
rs919642 OA 
OA_kneehi
p OA_knee 
T/A 0.27 1.05 1.04, 1.06 8.55E-15 0.41 0 
rs1330349 OA_hip 
 
C/G 0.58 1.08 1.06, 1.11 4.10E-11 0.71 0 
rs62578127 OA_hip 
 
C/T 0.63 1.09 1.06, 1.11 2.77E-12 0.54 0 
rs17659798 OA_kneehip 
 
A/C 0.71 1.06 1.04, 1.07 2.06E-10 0.86 0 
rs11031191 OA 
 
T/G 0.35 1.03 1.02, 1.05 1.42E-08 0.95 0 
rs10896015 OA_hip 
 
G/A 0.73 1.08 1.05, 1.11 2.74E-09 0.36 0 
rs34419890 OA_hip 
 
T/C 0.93 1.13 1.09, 1.18 1.99E-08 0.75 0 
rs1149620 OA 
 
T/A 0.57 1.04 1.02, 1.05 6.93E-10 0.90 0 
rs79056043 OA_hip 
 
G/A 0.05 1.18 1.12, 1.24 1.33E-09 0.14 53 
rs317630 OA 
 
T/C 0.27 1.04 1.02, 1.05 1.97E-08 0.75 0 
rs11105466 OA_kneehip 
 
A/G 0.42 1.04 1.03, 1.06 2.15E-08 0.26 22.6 
rs2171126 OA 
OA_kneehi
p 
T/C 0.51 1.03 1.02, 1.05 9.07E-10 0.26 21.5 
rs11059094 OA_hip 
 
T/C 0.48 1.08 1.05, 1.1 7.38E-11 0.44 0 
rs56116847 OA_knee 
OA   
OA_kneehi
p 
A/G 0.36 1.06 1.04, 1.08 3.19E-10 0.05 74.2 
rs35912128 OA_knee 
 
AT/A 0.17 1.08 1.05, 1.11 2.18E-08 1.00 0 
rs35206230 OA 
OA_kneehi
p 
T/C 0.67 1.04 1.03, 1.05 1.48E-12 0.86 0 
rs6499244 OA_knee 
OA_kneehi
p 
A/T 0.56 1.06 1.04, 1.08 3.88E-11 0.74 0 
rs1126464 OA 
 
G/C 0.76 1.04 1.03, 1.06 1.56E-10 0.07 69.3 
rs35087650 OA_knee 
 
ATT/A 0.26 1.07 1.05, 1.1 1.18E-09 1.00 0 
rs2953013 OA_kneehip 
 
C/A 0.3 1.05 1.04, 1.07 3.07E-10 0.87 0 
rs62063281 OA_hip 
 
G/A 0.22 1.1 1.07, 1.13 5.30E-12 0.91 0 
rs547116051 OA 
 
AC/A 0.001 1.83 1.49, 2.26 1.50E-08 1.00 0 
rs7222178 OA_hip 
 
A/T 0.2 1.1 1.07, 1.13 3.78E-11 0.59 0 
rs8067763 OA_knee 
 
G/A 0.41 1.06 1.04, 1.08 2.39E-09 0.35 0 
rs10502437 OA 
 
G/A 0.6 1.03 1.02, 1.04 2.50E-08 0.69 0 
rs1560707 OA 
 
T/G 0.37 1.04 1.03, 1.05 1.35E-13 0.45 0 
rs75621460 OA 
OA_kneehi
p 
A/G 0.03 1.16 1.12, 1.2 1.62E-15 0.58 0 
rs4252548 OA_hip 
 
T/C 0.02 1.32 1.22, 1.43 1.96E-12 0.05 73 
rs2836618 OA_hip 
OA_kneehi
p 
A/G 0.26 1.09 1.06, 1.12 3.20E-11 0.02 82.6 
rs528981060 OA 
 
A/G 0.001 1.68 1.4, 2.02 2.37E-08 1.00 0 
Previously reported loci 
         
rs2820443 OA_kneehip 
OA_hip             
OA 
C/T 0.3 1.06 1.04, 1.07 6.01E-11 0.82 0 
rs3771501 OA 
OA_hip 
OA_kneehi
p 
A/G 0.47 1.05 1.03, 1.06 4.24E-16 0.67 0 
rs3774355 OA_hip 
OA_kneehi
p 
A/G 0.36 1.09 1.07, 1.12 8.20E-14 0.12 59 
rs2396502 OA_hip 
OA_kneehi
p 
C/A 0.6 1.09 1.06, 1.11 2.12E-12 0.74 0 
rs12209223 OA_hip 
 
A/C 0.1 1.17 1.13, 1.21 3.88E-16 0.26 22 
rs10974438 OA 
OA_kneehi
p 
A/C 0.65 1.03 1.02, 1.05 1.34E-08 0.36 0 
rs34687269 OA_hip 
 
A/T 0.53 1.09 1.06, 1.11 1.67E-12 0.70 0 
rs10492367 OA_hip 
OA_kneehi
p 
T/G 0.19 1.16 1.13, 1.2 1.25E-24 0.25 24.5 
rs4775006 OA_knee 
 
A/C 0.41 1.06 1.04, 1.08 8.40E-10 0.08 68.3 
rs12901372 OA_hip 
 
C/G 0.53 1.08 1.06, 1.11 3.46E-11 0.13 56.2 
rs9930333 OA_kneehip 
 
G/T 0.42 1.05 1.03, 1.06 1.52E-09 0.04 75.8 
rs143384 OA_knee 
OA_kneehi
p OA 
A/G 0.6 1.1 1.08, 1.12 4.77E-23 0.37 0 
 344 
Trait: Osteoarthritis trait most significantly associated with variant in the meta-analysis stage; Other 345 
Traits: Other osteoarthritis traits with genome-wide significant association following meta-analysis; 346 
EA/NEA: Effect allele/non-effect allele; WEAF: Weighted effect allele frequency between UK Biobank 347 
and arcOGEN; OR: Odds ratio; OR_95CI: Lower bound of the 95% credible interval of the odds ratio, 348 
upper bound of the 95% credible interval of the odds ratio; PV: P value (two-sided); q_pv: P value of 349 
Cochrans Q measure of heterogeneity; i2: I² statistic describing the percentage of variation across 350 
studies that is due to heterogeneity rather than chance; OA: osteoarthritis; OA_hip: Hip 351 
osteoarthritis; OA_knee: Knee osteoarthritis; OA_kneehip: Knee and/or hip osteoarthritis. 352 
 353 
 354 
Table 2: Translational context for selected osteoarthritis-associated genes. 355 
 356 
Gene OA 
phenotype 
OA locus Chr: 
index variant 
MOA 
needed for 
OA, if 
known

 
Drug 
targeting OA 
gene 
Dev. Phase Molecul
e type 
Drug 
MOA 
Current 
Indication(s) 
TGFB1 OA; 
OA_kneehip 
Chr19: 
rs75621460 
Agonist / 
upregulator 
INVOSSA Registered Cell 
therapy 
јexpressi
on 
Knee osteoarthritis
GDF5 OA_knee; 
OA_kneehip
; OA 
Chr20: rs143384 Agonist / 
upregulator 
HMR-4052 Clinical 
development 
Protein јsignallin
g 
Regeneration, 
cartilage, 
intervertebral disc 
FGF18 OA_kneehip Chr5: rs3884606 
 
Agonist / 
upregulator 
AS-902330 Clinical 
development 
Protein јsignallin
g 
Osteoarthritis, 
cartilage 
regeneration 
CTSK OA; OA_hip 1:150214028 
_CT_C 
Unknown CTSK inhibitor Clinical 
development 
SM Inhibitor Osteoarthritis
IL11 OA_hip chr19: rs4252548 ј IL11 
signalling? 
Oprelvekin Approved Protein ј IL11 
signalling 
Thrombocytopenia
DPEP1 OA Chr16: 
rs1126464 
Unknown CILASTATIN Approved SM Inhibitor Co-administered 
with imipenem 
(antibiotic) to 
prolong effective 
dose 
DIABLO OA_hip Chr12:  
rs11059094 
 
Unknown LCL-161 Clinical 
development 
SM SMAC 
mimetic 
and IAP 
inhibitor 
Breast cancer, 
leukemia, 
myeloma 
CRHR1 OA_hip Chr17:  
rs62063281 
Inhibitor NBI-74788 Clinical 
development 
SM Antagonis
t 
Adrenal 
insufficiency, 
primary, 
congenital 
MAPT OA_hip Chr17:  
rs62063281 
Inhibitor flortaucipir F 
18, Leuco-
methylthionin
ium 
Clinical 
development 
SM Tau 
aggregati
on 
inhibitor 
Alzheimer's 
disease 
TNFSF15 OA; OA_hip; 
OA_kneehip
; OA_knee 
Chr9: rs919642, 
rs1330349 
Unknown PF-06480605
 
Clinical 
development 
Ab Inhibitor Ulcerative colitis, 
Wet AMD  
OA: osteoarthritis; OA_hip: Hip osteoarthritis; OA_knee: Knee osteoarthritis; OA_kneehip: Knee 357 
and/or hip osteoarthritis; SM: small molecule; Ab: Antibody; MOA: mechanism of action of a 358 
therapeutic; Based on functional evidence supporting the gene as an osteoarthritis risk factor. 359 
Criteria for inclusion of OA locus gene: target has a therapeutic approved or in clinical 360 
development; therapeutic with OA indication and/or target eQTL colocalization with index variant 361 
and/or target missense variant with posterior probability of colocalization >0.5. Drug data compiled 362 
from Chembl (URLs) and Clinical trials.gov (URLs). 363 
  364 
ONLINE METHODS 365 
 366 
Studies  367 
UK Biobank: UK Biobank is a cohort of 500,000 participants aged 40-69 years recruited between 368 
2006 and 2010 in 22 assessment centres throughout the UK35. The assessment visit included 369 
electronic signed consent; a self-completed touch-screen questionnaire; brief computer-assisted 370 
interview; physical and functional measures; and collection of biological samples and genetic data. 371 
This work was based on the third UK Biobank release, which includes the full set of the 500,000 372 
genotypes imputed on the Haplotype Reference Consortium36 and the 1000 Genomes Consortium37.  373 
The case and control definition, genotyping, imputation, and association testing are described in 374 
Supplementary Note. 375 
 376 
Arthritis Research UK Osteoarthritis Genetics (arcOGEN)  cases: arcOGEN is a collection of 377 
unrelated, UK-based individuals of European ancestry with knee and/or hip osteoarthritis from the 378 
arcOGEN Consortium9,38. Cases were ascertained based on clinical evidence of disease to a level 379 
requiring joint replacement or radiographic evidence of disease (KellgrenLawrence grade ш2). The 380 
arcOGEN study was ethically approved, and all subjects used in this study provided written, informed 381 
consent. 382 
United Kingdom Household Longitudinal Study (UKHLS)  controls: The UKHLS, also known as 383 
Understanding Society, is a longitudinal panel survey of 40,000 UK households (England, Scotland, 384 
Wales and Northern Ireland) representative of the UK population. Participants are surveyed 385 
annually since 2009 and contribute information relating to their socioeconomic circumstances, 386 
attitudes, and behaviours via a computer assisted interview. The study includes phenotypical data 387 
for a representative sample of participants for a wide range of social and economic indicators as well 388 
as a biological sample collection encompassing biometric, physiological, biochemical, and 389 
haematological measurements and self-reported medical history and medication use. The UKHLS has 390 
been approved by the University of Essex Ethics Committee and informed consent was obtained 391 
from every participant. The genotyping, imputation and association testing have been previously  392 
described9,39,40 (Supplementary Note).  393 
 394 
Meta-analysis 395 
We meta-analysed the UK Biobank and arcOGEN datasets using fixed effects inverse-variance 396 
weighted meta-analysis in METAL41. We performed meta-analyses across osteoarthritis definitions 397 
using summary statistics from the UK Biobank and arcOGEN cohorts, and defined genome-wide 398 
significance based on the meta-analysis combined P value as outlined below.  399 
 400 
Significance threshold 401 
The osteoarthritis traits analysed in this study are highly correlated. To calculate ܯ	?݂݁  ݂the effective 402 
number of independent traits, we estimated the genetic correlation matrix between the 4 403 
osteoarthritis traits (Supplementary Table 1) using LDscore42 with genome-wide summary statistics 404 
of common-frequency variants in the UK Biobank dataset. We then calculated ܯ	?݂݁  ݂ from the 405 
eigenvalues ߣ	?݅of the correlation matrix43: 406 
 407 408 
ܯ௘௙௙ ൌ ܯ െ෍ሾܫሺߣ௜ ൐ 	 ?ሻሺߣ௜ െ 	 ?ሻሿெ௜ୀଵ  409 
For the ܯ ൌ 4 osteoarthritis phenotypes in this study, ܯ	?݂݂݁ ൌ1Ǥ6046. We therefore use Pч3x10-8 410 
as the threshold corrected for the effective number of traits to report genome wide significance. 411 
 412 
Statistical independence 413 
To define independent signals within a GWAS, we performed physical clumping using a simple 414 
iterative procedure. We rank all variants that reach a P value threshold according to their P value. 415 
The variant with the smallest P value is considered the index variant of that signal and any variants 416 
within 1MB region either side of that index variant that reach the pre-defined P value threshold are 417 
clumped with that variant. We repeat the procedure until no more variants that reach the pre-418 
defined P value threshold exist that have not been assigned to a physical clump. To test that the 419 
index variants defined by this procedure are statistically independent, we performed an 420 
approximate stepwise model selection procedure, as implemented by COJO in GCTA
7
. An 421 
independent signal in a region is declared if its P value of association in the stepwise regression is 422 
less than 3x10-8. LD calculations were based on the full UK Biobank imputed set. 423 
 424 
To define independent signals across the four osteoarthritis GWAS, we performed reciprocal 425 
approximate conditional analyses, as implemented by COJO in GCTA7, of each index variant of one 426 
GWAS conditioned on each index variant of the other GWAS. A signal between two GWAS is 427 
considered to be the same if the P value of an index variant of one GWAS conditioned on an index 428 
variant of the other GWAS is ч 10-5 or a P value difference between conditional and unconditional 429 
analysis of less than 2 orders of magnitude. 430 
 431 
To investigate statistical independence between index variants from each GWAS and previously 432 
reported variants, we performed approximate conditional analysis, as implemented by COJO in 433 
GCTA7, of each index variant conditional on all previously reported variants within 1Mb region, each 434 
one at a time. The index variant was considered independent from a previously reported variant if it 435 
had a conditional P ч 10-5 or a P value difference between conditional and unconditional analysis of 436 
less than 2 orders of magnitude. Variants were classified as known (denoting either a previously 437 
reported variant, or a variant for which the association signal disappears after conditioning on the 438 
lead variant of a previously reported locus) or newly identified (denoting a variant which is 439 
conditionally independent of previously reported loci).  440 
 441 
Fine-mapping 442 
We constructed regions for fine-mapping by taking a window of 1Mb either side of each index 443 
variant. Within each region, we performed an approximate stepwise model selection procedure, as 444 
implemented by COJO in GCTA7, using the meta-analysis summary statistics and LD calculations 445 
based on the UK Biobank cohort to determine the number of independent signals. We consider 446 
conditionally distinct signals those where the stepwise regression association reaches genome-wide 447 
significance (P<3.0x10-8).  We then perform single-SNP approximate association analyses conditional 448 
on the set of SNPs identified by the model selection procedure, again using COJO, and we calculate 449 
Wakefields asymptotic Bayes factors
8
 (ABF). In particular, when there is a single causal variant in 450 
the region, ABF is based on the marginal summary statistics of the meta-analysis. When there are 451 
multiple causal variants in the region, for each signal we calculate a set of ABF using the conditional 452 
summary statistics of the meta-analysis conditioned on all other signals. For each signal, we then 453 
calculate posterior probabilities of each variant being causal and a 95% credible set, which contains 454 
the minimum set of variants that jointly have at least 95% probability of including the causal variant. 455 
As this number can be large, we focus on the variants in the 95% credible set that have posterior 456 
probability of causality (PPC) over 3% and also on any variants in the 95% credible set with moderate 457 
or high consequence (irrespective of their PPC).  458 
 459 
Genetic correlation analysis 460 
To better understand the degree to which genetic architecture is shared across osteoarthritis and 461 
other complex traits, LD score regression5  was performed as implemented in the LDHub pipeline6 462 
(URLs). We calculated the genome-wide genetic correlation between each of the osteoarthritis 463 
definitions and all available 832 human traits and diseases (accessed 15-18 June 2018). Of these, 597 464 
traits were available within the UK Biobank resource. In each analysis, all variants in the major 465 
histocompatibility complex (MHC) region on chromosome 6 (2634 MB) were removed and only 466 
variants with rsIDs were included in the analyses, yielding 1203892 - 1204029 variants overlapping 467 
with LDHub. We used the Benjamini-Hochberg false discovery rate and the effective number of 468 
independent traits tested for multiple testing correction. The level of significance was set at FDR-469 
corrected P<0.05. 470 
 471 
Mendelian randomization 472 
We performed Mendelian randomization analyses using the MR-Base platform44. We tested the 473 
bidirectional causal associations of each of the four osteoarthritis datasets with 991 exposures/ 474 
outcomes in MR-Base. Statistical significance was considered at P<6.3x10-6. To follow up on pain 475 
associations, we performed analyses of knee and hip pain as an outcome after excluding all 476 
individuals self-reporting or hospital-diagnosed with osteoarthritis in UK Biobank. All instruments 477 
were aggressively clumped prior to analysis (LD r2<0.001) and inverse variance-weighted (IVW), 478 
Median-weighted, and MR-Egger analyses were performed for multi-variant instruments, and Wald 479 
ratio estimators were used to assess causality for single variant instruments.  480 
 481 
Transcriptome-wide association  482 
We used a gene-based approach, MetaXcan45, to test for associations between the osteoarthritis 483 
traits and predicted expression levels in 48 human tissues from GTEx V746. MetaXcan leverages a set 484 
of reference individuals for whom both gene expression and genetic variation have been measured 485 
to impute the cis-genetic component of expression into a much larger set using the elastic net 486 
model. It then correlates the imputed gene expression to the trait of interest and performs a 487 
transcriptome-wide association study to identify significant expression-trait associations. We used a 488 
conservative Bonferroni correction to account for the gene-tissue pairs (20,000 genes across 48 489 
tissues), leading to a significance threshold of 5.20x10-8. To reduce the effect of LD confounding on 490 
the MetaXcan results, when different causal SNPs are affecting expression levels and the phenotypic 491 
trait in a GWAS, we estimated the probability of colocalization of each GWAS and expression 492 
quantitative trait locus (eQTL) signal in each significant MetaXcan result using Coloc47 493 
(Supplementary Note, Supplementary Figure8, Supplementary Tables 8 and 9).  494 
 495 
Colocalization analysis 496 
To assess whether the genome-wide significant osteoarthritis signals colocalise with eQTL signals, 497 
and therefore potentially share a causal molecular mechanism, we employed the Coloc method47, 498 
which uses asymptotic Bayes factors with summary statistics and regional LD structure to estimate 499 
five posterior probabilities: no association with either GWAS or eQTL (PP0), association with GWAS 500 
only (PP1), association with eQTL only (PP2), association with GWAS and eQTL but two independent 501 
SNPs (PP3), and association with GWAS and eQTL having one shared SNP (PP4). A large posterior 502 
probability for PP4 indicates support for a single variant affecting both GWAS and eQTL studies. For 503 
each of the GWAS signals, we defined a 100kb region either side of the index variant, and tested for 504 
colocalization within the entire cis-region of any overlapping eQTLs (transcription start and end 505 
position of an eQTL gene plus and/or minus 1Mb, as defined by GTEx) in 48 human tissues from 506 
GTEx V746. A PP4 over or equal to 80% was considered as evidence for colocalization (Supplementary 507 
Note, Supplementary Table 7). 508 
 509 
Most colocalization methods, such as Coloc, rely on the availability of genome-wide eQTL results, 510 
which are not always readily available. For eQTL datasets with no publically available full summary 511 
statistics, we used an alternative approach that estimates the probability of colocalization using 512 
published top eQTL signals. First, we estimated the credible sets for the eQTLs using the Probabilistic 513 
Identification of Causal SNPs (PICS) method48 for each index SNP for each gene from 27 eQTL studies 514 
(Supplementary Table 6). PICS is a fine-mapping algorithm that assumes one causal signal tagged by 515 
a single index SNP per locus.  For neutral SNPs (SNPs whose association signals are due to LD with 516 
the causal SNP), the strength of association scales linearly with the r2 relationship/distance to the 517 
index SNP.  Under this assumption, PICS can estimate the posterior probability of a given SNP being 518 
causal using LD information from the 1000 Genomes database. Second, we generated PICs credible 519 
sets for osteoarthritis GWAS index SNPs. We then performed a colocalization analysis of the 520 
osteoarthritis GWAS and eQTL PICs credible sets using an adapted Coloc method49.  Given that PICs 521 
calculates the posterior probabilities for each SNP in the credible set, we bypassed the need for 522 
calculating the Bayes Factors using Wakefields approximate Bayes Factor method which is reliant on 523 
full summary statistics. Colocalizations with a posterior probability greater than 0.8 were considered 524 
positive. This method was benchmarked on other GWAS datasets, and we found the false positive 525 
rate to be no higher than the standard Coloc package.  526 
 527 
We observe evidence of colocalization in at least one tissue for 50 out of our 64 loci using any of the 528 
3 methods (MetaXcan, Coloc, Piccolo), 41 of which are at newly associated osteoarthritis signals 529 
(Supplementary Table 7). MetaXcan alone identified 119 genes, Coloc 113 and Piccolo 58, while the 530 
overlap of all 3 methods implicate 20 genes (TGFA, ILF3, CSK, CYP1A1, ULK3, CHMP1A, TSKU, 531 
SUPT3H, GNL3, NT5DC2, LMX1B, SMAD3, MLXIP, COLGALT2, FAM89B, UQCC1, NFAT5, ALDH1A2, 532 
FAM53A, FGFR3; Supplementary Figure 7). 533 
 534 
Heritability estimation 535 
To investigate the narrow sense heritability for the four osteoarthritis disease definitions, we ran 536 
LDscore42, which uses summary statistics at common-frequency variants genome-wide (independent 537 
of P value thresholds) and LD estimates between variants while accounting for sample overlap. To 538 
calculate the population prevalence in the UK (65 million people), we consulted Arthritis Research 539 
UK figures: 8.75 million people have symptomatic osteoarthritis, while 2.46 and 4.11 million people 540 
have osteoarthritis of the hip and the knee, respectively. We assumed that 2.46+4.11 million people 541 
have osteoarthritis of the hip and/or the knee. We estimated the phenotypic variance explained by 542 
the 99previously and newly reported variants that reached genome-wide significance in the meta-543 
analysis between UK Biobank and arcOGEN, as a function of allele frequency (Figure 2; 544 
Supplementary Table 17). The phenotypic variance explained by a variant is ሻ ݈݊ሺܱܴሻଶ ൈ 	 ? ൈ ܧܣܨ ൈ545 ሺ	 ? െ ܧܣܨሻ, whereሺܱܴሻis the natural logarithm of the OR of the variant in the meta-analysis and 546 ܧܣܨis its weighted effect allele frequency across UK Biobank and arcOGEN. Variants associated with 547 
hip osteoarthritis tend to have larger effect size estimates and hence explain more of the phenotypic 548 
variability (Figure 2; Supplementary Table 17). The hip osteoarthritis dataset is the smallest in both 549 
the UK Biobank and arcOGEN cohorts (18% and 59% fewer cases compared to knee osteoarthritis 550 
and osteoarthritis at any joint in UK Biobank, respectively). 551 
 552 
Pathway analysis 553 
We performed gene-set analyses for each of the osteoarthritis phenotypes separately, using 554 
MAGMA v1.0650. We mapped variants to 19,427 protein-coding genes (NCBI 37.3), including a 10kb 555 
window on either side of the gene. We then computed gene P values based on individual variant 556 
association P values. We used the snp-wise=mean model, which calculates the mean of the ʖ2-557 
statistic amongst the single variant P values in each gene, and applied default MAGMA QC steps. 558 
Genotype data of 10,000 individuals (subset of self-reported plus hospital-diagnosed osteoarthritis 559 
at any site analysis), were used to calculate LD (as measured by r2). We carried out a one-sided 560 
competitive gene-set analysis for each phenotype, implemented as a linear regression model on a 561 
gene data matrix created internally from the gene-based results. Briefly, this converts the gene-562 
based P values to Z-scores, and tests if the mean association with the phenotype of genes in the 563 
gene set is greater than that of all other genes. We used Kyoto Encyclopedia of Genes and Reactome 564 
(accessed through MSigDB113 (version 5.2) on 23 January 2017). We also downloaded Gene 565 
Ontology (GO) biological process and molecular function gene annotations from Ensembl (version 566 
87). We used annotations with the following evidence codes: a) Inferred from Mutant Phenotype 567 
(IMP); b) Inferred from Physical Interaction (IPI); c) Inferred from Direct Assay (IDA); d) Inferred from 568 
Expression Pattern (IEP); and e) Traceable Author Statement (TAS). KEGG/Reactome and GO 569 
annotations were analysed separately and only pathways that contained between 20 and 200 genes 570 
were included (594 for KEGG/Reactome, 619 for GO). We used MAGMAs built-in permutation 571 
method (k=10,000 permutations) to produce corrected competitive P values with a family-wise error 572 
rate (FWER) of 5%. We then further adjusted these corrected competitive P values for the effective 573 
number of independent traits tested (1.6046). 574 
 575 
We also performed gene set enrichment analysis by using DEPICT (URLs) and PASCAL (URLs). DEPICT 576 
version 1 rel194 was downloaded from GitHub (URLs) on 14/06/2018. We run DEPICT separately in 577 
each of the four osteoarthritis definitions for the variants with a meta-analysis P<1x10-5. Briefly, 578 
DEPICT first clumped the variants with P<1x10-5 using 500 kb flanking regions as physical distance 579 
threshold and an r2>0.1 with PLINK51 to obtain lists of independent SNPs, resulting in 864 clumps. 580 
Variants within the major histocompatibility complex region on chromosome 6 were excluded. 581 
DEPICT analyses were conducted using the default settings: 50 repetitions to compute FDR and 500 582 
permutations based on 500 null GWAS to compute P values adjusted for gene length. All 14,461 583 
available reconstituted gene sets were used representing a wide spectrum of biological and mouse 584 
phenotypic annotations. We also used the method implemented in PASCAL to perform gene set 585 
enrichment analysis which accounts for LD structure in the genome and particularly of highly 586 
correlated chromosomal regions containing multiple genes that can negatively impact the results of 587 
the analysis. In this approach, variants were first mapped to genes, including a 10kb window on 588 
either side of the gene. We then computed gene scores by aggregating the single-marker association 589 
values with the LD structure. Finally, the scores of genes that belong to the same pathways (i.e. gene 590 
sets) were used to compute pathway scores and determine the statistical significance of the 591 
association between the pathway and each of the osteoarthritis phenotypes. Here we used exactly 592 
the same pathways of the MAGMA analysis. The gene and the pathway scores were performed by 593 
using the sum gene score and the chi-squared approach respectively, as implemented in PASCAL. All 594 
pathway P values obtained by either software were adjusted for multiple testing correction by using 595 
FDR and the effective number of independent traits. The level of significance was set at FDR-596 
corrected P<0.05. 597 
 598 
Monogenic enrichment analysis 599 
We compiled a systematic list of genes causing bone phenotypes in humans by scanning the 600 
STOPGAP database 52, which uses OMIM (URLs) and Orphanet (URLs) to define genes underlying 601 
monogenic/Mendelian diseases. We selected all genes causing monogenic diseases and annotated 602 
with MeSH terms (Medical Subject Headings) related to bone, cartilage or joint disease, including: 603 
bone disease, developmental, osteochondrodysplasias, osteogenesis imperfecta, 604 
osteoporosis, osteopetrosis, arthritis, juvenile and arthrogryposis. Other bone-, cartilage or 605 
joint related mesh terms linked to less than 10 genes in the STOPGAP database were excluded from 606 
the analysis. Additionally, we selected a list of well-validated genes underlying syndromic or non-607 
syndromic forms of early onset osteoarthritis (EO-OA) from a review by Aury-Landas et al.53. For 608 
enrichment analysis, genes residing within 500kb of each index variant identified in our GWAS were 609 
considered as osteoarthritis loci, and the rest of the genes in the genome associated to any mesh 610 
term in STOPGAP were considered non-osteoarthritis loci. We built a 2x2 table by counting the 611 
number of genes annotated to each of the above-mentioned MeSH terms among osteoarthritis and 612 
non-osteoarthritis loci. We assessed evidence for enrichment using a Fishers exact test.  613 
 614 
Transcriptomic and proteomic analyses 615 
Patients and samples: We collected cartilage samples from 38 patients undergoing total joint 616 
replacement surgery: 12 knee osteoarthritis patients (cohort 1; 2 women, 10 men, age 50-88 years); 617 
knee osteoarthritis patients (cohort 2; 12 women 5 men, age 54-82 years); 9 hip osteoarthritis 618 
patients (cohort 3; 6 women, 3 men, age 44-84 years). We collected matched intact and degraded 619 
cartilage samples from each patient. Cartilage was separated from bone and chondrocytes were 620 
extracted from each sample. From each isolated chondrocyte sample, we extracted DNA, RNA and 621 
protein. All patients provided full written informed consent prior to participation. The human 622 
biological samples were sourced ethically and their research use was in accord with the terms of the 623 
informed consents under an IRB/EC approved protocol. All sample collection, DNA, RNA and protein 624 
analysis steps are described in detail in Steinberg et al
54
. 625 
 626 
Proteomics and RNA sequencing: Proteomics analysis was performed on intact and degraded 627 
cartilage samples from 24 individuals (15 from cohort 2, 9 from cohort 3). We performed a gene 628 
expression analysis on samples from all 38 patients (Supplementary Note).  629 
 630 
Animal model data 631 
The presence of abnormal skeletal phenotypes in mice was evaluated for all genes within 500kb of 632 
an osteoarthritis index variant and extracted from Open Targets55. This platform integrates all 633 
abnormal phenotype annotations for mutations in mouse genes reported in the literature and 634 
curated at MGI (URLs). Given the list of genes located less than 1 Mb away of the 64 genome-wide 635 
significant signals for osteoarthritis, abnormal skeletal system phenotypes from mutant mice were 636 
extracted systematically for all mouse orthologs of the human genes using the programmatic 637 
interface of the Open Targets platform (Supplementary Table 21). For instance, mutant mice 638 
homozygous for a targeted mutation of Smad3 (the ortholog of human SMAD family member 3) 639 
developed degenerative joint disease by progressive loss of articular cartilage56. Additional manual 640 
PubMed searches were conducted on selected genes to obtain information regarding animal models 641 
specific for osteoarthritis (Supplementary Table 20). 642 
 643 
DATA AVAILABILITY 644 
All RNA sequencing data have been deposited to the European Genome/Phenome Archive (cohort 1: 645 
EGAD00001001331; cohort 2: EGAD00001003355; cohort 3: EGAD00001003354). Genotype data of 646 
the arcOGEN cases and UKHLS controls have been deposited at the European Genome-phenome 647 
Archive under study accession numbers EGAS00001001017 and EGAS00001001232, respectively. 648 
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 705 
Editoria l Sum m ary:  706 
Genome-wide m eta-analysis of UK Biobank and arcOGEN (77,052 cases and 378,169 cont rols)  707 
ident ifies 52 new osteoarthrit is r isk loci. I ntegrated eQTL colocalizat ion, fine-m apping, and rare 708 
disease data ident ify putat ive effector genes for osteoarthr it is. 709 

Risk Allele Frequency
O
d
d
s
 R
a
ti
o
0 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 1
1
1
.1
1
.2
1
.3
1
.4
1
.5
1
.6
1
.7
1
.8
1
.9
2
  
  





    





All OA New
All OA Known
Hip OA New
Hip OA Known
Knee OA New
Knee OA Known
Knee and/or hip OA New
Knee and/or hip OA Known
All OA
Hip OA
Knee OA
Knee and/or hip OA
